Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin-Etoposide vs Non-Platinum Regimen in Extensive SCLC
NCT00658580Phase 3Completed
- Sponsor
- European Lung Cancer Working Party
- Start
- Apr 2000
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of epirubicin and ifosfamide in Small Cell Lung Cancer (SCLC) (2 arms), sponsored by European Lung Cancer Working Party. Primary endpoint: Overall Survival. Started Apr 2000; status: completed.
02
Drugs
epirubicinifosfamide
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT00658580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658580.